Skip to main content
SpringerLink
Log in

Solitary Plasmacytoma

  • Chapter
  • First Online:
Multiple Myeloma

  • 2223 Accesses

Abstract

Solitary plasmacytoma (SP) is the clinical condition characterized by the localized proliferation of clonal plasma cells. The definition of SP has been evolving as a result of improvement in imaging technology as well as the availability of more sensitive techniques that can detect small populations of clonal plasma cells in the bone marrow. Patients with SP do not have other lytic or sclerotic bone lesions or soft tissue masses, hypercalcemia, renal insufficiency, or anemia and no involvement of the bone marrow by clonal plasma cells (Table 16.1) [1–3]. Some series have included patients with two bone lesions and less than 5 or 10 % clonal plasma cells in the bone marrow [4–10]. The presence of a monoclonal protein in the serum or urine or the presence of elevated immunoglobulin free light chain (FLC) does not exclude the diagnosis. On the contrary, such biomarkers may provide important prognostic information and may guide management. SP is further divided into two entities: solitary plasmacytoma of bone (SPB) and extramedullary plasmacytoma (EMP) where the plasma cell clone generally arises from lymphoid tissues away from the bone marrow microenvironment that normally hosts these cells. SP is quite uncommon and constitutes less than 5 % of all plasma cell neoplasms [11]. Out of 45,366 patients with a plasma cell proliferative disorder seen at Mayo Clinic, Rochester, MN, between 1960 and 2011, 883 patients were diagnosed with SP (2 %). SPB is more common than EMP by a ratio of at least 2:1 [2, 12], although the comprehensive literature review by Alexiou et al. suggests a ratio closer to 5:1 [13]. SP is more common in males (~70 %) and the median age at diagnosis varies from 55 to 60 years, depending on the study [2, 5, 7, 8, 14, 15]. Almost a third of patients are below 50 years of age at the time of diagnosis. Thus, patients diagnosed with SP are significantly younger than those diagnosed with multiple myeloma.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Dimopoulos MA, Moulopoulos LA, Maniatis A, Alexanian R. Solitary plasmacytoma of bone and asymptomatic multiple myeloma. Blood. 2000;96(6): 2037–44.

    PubMed  CAS  Google Scholar 

  2. Reed V, Shah J, Medeiros LJ, et al. Solitary plasmacytomas: outcome and prognostic factors after definitive radiation therapy. Cancer. 2011;117(19):4468–74.

    Article  PubMed  Google Scholar 

  3. Group IMW. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol. 2003;121(5): 749–57.

    Article  Google Scholar 

  4. Corwin J, Lindberg RD. Solitary plasmacytoma of bone vs. extramedullary plasmacytoma and their relationship to multiple myeloma. Cancer. 1979;43(3): 1007–13.

    Article  PubMed  CAS  Google Scholar 

  5. Bataille R, Sany J. Solitary myeloma: clinical and prognostic features of a review of 114 cases. Cancer. 1981;48(3):845–51.

    Article  PubMed  CAS  Google Scholar 

  6. McLain RF, Weinstein JN. Solitary plasmacytomas of the spine: a review of 84 cases. J Spinal Disord. 1989;2(2):69–74.

    Article  PubMed  CAS  Google Scholar 

  7. Dingli D, Kyle RA, Rajkumar SV, et al. Immunoglobulin free light chains and solitary plasmacytoma of bone. Blood. 2006;108(6):1979–83.

    Article  PubMed  CAS  Google Scholar 

  8. Warsame R, Gertz MA, Lacy MQ, et al. Trends and outcomes of modern staging of solitary plasmacytoma of bone. Am J Hematol. 2012;87(7):647–51.

    Article  PubMed  Google Scholar 

  9. Knobel D, Zouhair A, Tsang RW, et al. Prognostic factors in solitary plasmacytoma of the bone: a multicenter Rare Cancer Network study. BMC Cancer. 2006;6:118.

    Article  PubMed  Google Scholar 

  10. Tsang RW, Gospodarowicz MK, Pintilie M, et al. Solitary plasmacytoma treated with radiotherapy: impact of tumor size on outcome. Int J Radiat Oncol Biol Phys. 2001;50(1):113–20.

    Article  PubMed  CAS  Google Scholar 

  11. Dimopoulos MA, Goldstein J, Fuller L, Delasalle K, Alexanian R. Curability of solitary bone plasmacytoma. J Clin Oncol. 1992;10(4):587–90.

    PubMed  CAS  Google Scholar 

  12. Dimopoulos MA, Hamilos G. Solitary bone plasmacytoma and extramedullary plasmacytoma. Curr Treat Options Oncol. 2002;3(3):255–9.

    Article  PubMed  Google Scholar 

  13. Alexiou C, Kau RJ, Dietzfelbinger H, et al. Extramedullary plasmacytoma: tumor occurrence and therapeutic concepts. Cancer. 1999;85(11):2305–14.

    Article  PubMed  CAS  Google Scholar 

  14. Bachar G, Goldstein D, Brown D, et al. Solitary extramedullary plasmacytoma of the head and neck—long-term outcome analysis of 68 cases. Head Neck. 2008;30(8):1012–9.

    Article  PubMed  Google Scholar 

  15. Lopes da Silva R. Extramedullary plasmacytoma of the small intestine: clinical features, diagnosis and treatment. J Dig Dis. 2012;13(1):10–8.

    Article  PubMed  Google Scholar 

  16. Frassica DA, Frassica FJ, Schray MF, Sim FH, Kyle RA. Solitary plasmacytoma of bone: Mayo Clinic experience. Int J Radiat Oncol Biol Phys. 1989;16(1): 43–8.

    Article  PubMed  CAS  Google Scholar 

  17. Fonseca R, Barlogie B, Bataille R, et al. Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res. 2004;64(4):1546–58.

    Article  PubMed  CAS  Google Scholar 

  18. Bergsagel PL, Kuehl WM. Molecular pathogenesis and a consequent classification of multiple myeloma. J Clin Oncol. 2005;23(26):6333–8.

    Article  PubMed  CAS  Google Scholar 

  19. Chng WJ, Santana-Davila R, Van Wier SA, et al. Prognostic factors for hyperdiploid-myeloma: effects of chromosome 13 deletions and IgH translocations. Leukemia. 2006;20(5):807–13.

    Article  PubMed  CAS  Google Scholar 

  20. Zhan F, Huang Y, Colla S, et al. The molecular classification of multiple myeloma. Blood. 2006;108(6): 2020–8.

    Article  PubMed  CAS  Google Scholar 

  21. Chng WJ, Kuehl WM, Bergsagel PL, Fonseca R. Translocation t(4;14) retains prognostic significance even in the setting of high-risk molecular signature. Leukemia. 2008;22(2):459–61.

    Article  PubMed  CAS  Google Scholar 

  22. Avet-Loiseau H, Attal M, Campion L, et al. Long-term analysis of the IFM 99 trials for myeloma: cytogenetic abnormalities [t(4;14), del(17p), 1q gains] play a major role in defining long-term survival. J Clin Oncol. 2012;30(16):1949–52.

    Article  PubMed  Google Scholar 

  23. Stewart AK, Bergsagel PL, Greipp PR, et al. A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy. Leukemia. 2007;21(3):529–34.

    Article  PubMed  CAS  Google Scholar 

  24. Kapoor P, Kumar S, Fonseca R, et al. Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasone. Blood. 2009;114(3):518–21.

    Article  PubMed  CAS  Google Scholar 

  25. Avet-Loiseau H, Facon T, Daviet A, et al. 14q32 translocations and monosomy 13 observed in monoclonal gammopathy of undetermined significance delineate a multistep process for the oncogenesis of multiple myeloma. Intergroupe Francophone du Myelome. Cancer Res. 1999;59(18):4546–50.

    PubMed  CAS  Google Scholar 

  26. Fonseca R, Ahmann GJ, Jalal SM, et al. Chromosomal abnormalities in systemic amyloidosis. Br J Haematol. 1998;103(3):704–10.

    Article  PubMed  CAS  Google Scholar 

  27. Bink K, Haralambieva E, Kremer M, et al. Primary extramedullary plasmacytoma: similarities with and differences from multiple myeloma revealed by interphase cytogenetics. Haematologica. 2008;93(4):623–6.

    Article  PubMed  Google Scholar 

  28. Chng WJ, Price-Troska T, Gonzalez-Paz N, et al. Clinical significance of TP53 mutation in myeloma. Leukemia. 2007;21(3):582–4.

    Article  PubMed  CAS  Google Scholar 

  29. Vasef MA, Medeiros LJ, Yospur LS, Sun NC, McCourty A, Brynes RK. Cyclin D1 protein in multiple myeloma and plasmacytoma: an immunohistochemical study using fixed, paraffin-embedded tissue sections. Mod Pathol. 1997;10(9):927–32.

    PubMed  CAS  Google Scholar 

  30. Kumar S, Fonseca R, Ketterling RP, et al. Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics. Blood. 2012;119(9): 2100–5.

    Article  PubMed  CAS  Google Scholar 

  31. Dispenzieri A. POEMS syndrome: update on diagnosis, risk-stratification, and management. Am J Hematol. 2012;87(8):804–14.

    Article  PubMed  Google Scholar 

  32. Dispenzieri A, Kyle RA, Lacy MQ, et al. POEMS syndrome: definitions and long-term outcome. Blood. 2003;101(7):2496–506.

    Article  PubMed  CAS  Google Scholar 

  33. Medini E, Rao Y, Levitt SH. Solitary extramedullary plasmacytoma of the upper respiratory and digestive tracts. Cancer. 1980;45(11):2893–6.

    Article  PubMed  CAS  Google Scholar 

  34. Kapadia SB, Desai U, Cheng VS. Extramedullary plasmacytoma of the head and neck. A clinicopathologic study of 20 cases. Medicine. 1982;61(5):317–29.

    Article  PubMed  CAS  Google Scholar 

  35. Manganaris A, Conn B, Connor S, Simo R. Uncommon presentation of nasopharyngeal extramedullary plasmacytoma: a case report and literature review. B-ENT. 2010;6(2):143–6.

    PubMed  CAS  Google Scholar 

  36. Nagai K, Ando K, Yoshida H, et al. Response of the extramedullary lung plasmacytoma with pleural effusion to chemotherapy. Ann Hematol. 1997;74(6): 279–81.

    Article  PubMed  CAS  Google Scholar 

  37. Bourtsos EP, Bedrossian CW, De Frias DV, Nayar R. Thyroid plasmacytoma mimicking medullary carcinoma: a potential pitfall in aspiration cytology. Diagn Cytopathol. 2000;23(5):354–8.

    Article  PubMed  CAS  Google Scholar 

  38. Yu SC, Chen SU, Lu W, Liu TY, Lin CW. Expression of CD19 and lack of miR-223 distinguish extramedullary plasmacytoma from multiple myeloma. Histopathology. 2011;58(6):896–905.

    Article  PubMed  Google Scholar 

  39. Knowling MA, Harwood AR, Bergsagel DE. Comparison of extramedullary plasmacytomas with solitary and multiple plasma cell tumors of bone. J Clin Oncol. 1983;1(4):255–62.

    PubMed  CAS  Google Scholar 

  40. Liebross RH, Ha CS, Cox JD, Weber D, Delasalle K, Alexanian R. Solitary bone plasmacytoma: outcome and prognostic factors following radiotherapy. Int J Radiat Oncol Biol Phys. 1998;41(5):1063–7.

    Article  PubMed  CAS  Google Scholar 

  41. Bolek TW, Marcus Jr RB, Mendenhall NP. Solitary plasmacytoma of bone and soft tissue. Int J Radiat Oncol Biol Phys. 1996;36(2):329–33.

    Article  PubMed  CAS  Google Scholar 

  42. Brinch L, Hannisdal E, Abrahamsen AF, Kvaloy S, Langholm R. Extramedullary plasmacytomas and solitary plasma cell tumours of bone. Eur J Haematol. 1990;44(2):132–5.

    Article  PubMed  CAS  Google Scholar 

  43. Galieni P, Cavo M, Avvisati G, et al. Solitary plasmacytoma of bone and extramedullary plasmacytoma: two different entities? Ann Oncol. 1995;6(7):687–91.

    PubMed  CAS  Google Scholar 

  44. Jackson A, Scarffe JH. Prognostic significance of osteopenia and immunoparesis at presentation in patients with solitary myeloma of bone. Eur J Cancer. 1990;26(3):363–71.

    Article  PubMed  CAS  Google Scholar 

  45. Holland J, Trenkner DA, Wasserman TH, Fineberg B. Plasmacytoma. Treatment results and conversion to myeloma. Cancer. 1992;69(6):1513–7.

    Article  PubMed  CAS  Google Scholar 

  46. Liebross RH, Ha CS, Cox JD, Weber D, Delasalle K, Alexanian R. Clinical course of solitary extramedullary plasmacytoma. Radiother Oncol. 1999;52(3): 245–9.

    Article  PubMed  CAS  Google Scholar 

  47. Wilder RB, Ha CS, Cox JD, Weber D, Delasalle K, Alexanian R. Persistence of myeloma protein for more than one year after radiotherapy is an adverse prognostic factor in solitary plasmacytoma of bone. Cancer. 2002;94(5):1532–7.

    Article  PubMed  CAS  Google Scholar 

  48. San Miguel JF, Gutierrez NC, Mateo G, Orfao A. Conventional diagnostics in multiple myeloma. Eur J Cancer. 2006;42(11):1510–9.

    Article  PubMed  Google Scholar 

  49. Jackson A, Scarffe JH. Upper humeral cortical thickness as an indicator of osteopenia: diagnostic significance in solitary myeloma of bone. Skeletal Radiol. 1991;20(5):363–7.

    Article  PubMed  CAS  Google Scholar 

  50. Moulopoulos LA, Dimopoulos MA, Weber D, Fuller L, Libshitz HI, Alexanian R. Magnetic resonance imaging in the staging of solitary plasmacytoma of bone. J Clin Oncol. 1993;11(7):1311–5.

    PubMed  CAS  Google Scholar 

  51. Lecouvet FE, Malghem J, Michaux L, et al. Skeletal survey in advanced multiple myeloma: radiographic versus MR imaging survey. Br J Haematol. 1999; 106(1):35–9.

    Article  PubMed  CAS  Google Scholar 

  52. Schirrmeister H, Buck AK, Bergmann L, Reske SN, Bommer M. Positron emission tomography (PET) for staging of solitary plasmacytoma. Cancer Biother Radiopharm. 2003;18(5):841–5.

    Article  PubMed  Google Scholar 

  53. Mulligan ME, Badros AZ. PET/CT and MR imaging in myeloma. Skeletal Radiol. 2007;36(1):5–16.

    Article  PubMed  Google Scholar 

  54. Salaun PY, Gastinne T, Frampas E, Bodet-Milin C, Moreau P, Bodere-Kraeber F. FDG-positron-emission tomography for staging and therapeutic assessment in patients with plasmacytoma. Haematologica. 2008;93(8):1269–71.

    Article  PubMed  Google Scholar 

  55. Nanni C, Rubello D, Zamagni E, et al. 18F-FDG PET/CT in myeloma with presumed solitary plasmocytoma of bone. In Vivo. 2008;22(4):513–7.

    PubMed  Google Scholar 

  56. Wiltshaw E. The natural history of extramedullary plasmacytoma and its relation to solitary myeloma of bone and myelomatosis. Medicine. 1976;55(3): 217–38.

    Article  PubMed  CAS  Google Scholar 

  57. Woodruff RK, Whittle JM, Malpas JS. Solitary plasmacytoma. I: extramedullary soft tissue plasmacytoma. Cancer. 1979;43(6):2340–3.

    Article  PubMed  CAS  Google Scholar 

  58. Jawad MU, Scully SP. Skeletal plasmacytoma: progression of disease and impact of local treatment; an analysis of SEER database. J Hematol Oncol. 2009;2:41.

    Article  PubMed  Google Scholar 

  59. Soutar R, Lucraft H, Jackson G, et al. Guidelines on the diagnosis and management of solitary plasmacytoma of bone and solitary extramedullary plasmacytoma. Br J Haematol. 2004;124(6):717–26.

    Article  PubMed  Google Scholar 

  60. Mendenhall CM, Thar TL, Million RR. Solitary plasmacytoma of bone and soft tissue. Int J Radiat Oncol Biol Phys. 1980;6(11):1497–501.

    Article  PubMed  CAS  Google Scholar 

  61. Mayr NA, Wen BC, Hussey DH, et al. The role of radiation therapy in the treatment of solitary plasmacytomas. Radiother Oncol. 1990;17(4):293–303.

    Article  PubMed  CAS  Google Scholar 

  62. Ozsahin M, Tsang RW, Poortmans P, et al. Outcomes and patterns of failure in solitary plasmacytoma: a multicenter Rare Cancer Network study of 258 patients. Int J Radiat Oncol Biol Phys. 2006;64(1): 210–7.

    Article  PubMed  Google Scholar 

  63. Weber DM. Solitary bone and extramedullary plasmacytoma. Hematology Am Soc Hematol Educ Program. 2005:373–6, PMID is 16304406.

    Google Scholar 

  64. Aviles A, Huerta-Guzman J, Delgado S, Fernandez A, Diaz-Maqueo JC. Improved outcome in solitary bone plasmacytomata with combined therapy. Hematol Oncol. 1996;14(3):111–7.

    Article  PubMed  CAS  Google Scholar 

  65. Delauche-Cavallier MC, Laredo JD, Wybier M, et al. Solitary plasmacytoma of the spine. Long-term clinical course. Cancer. 1988;61(8):1707–14.

    Article  PubMed  CAS  Google Scholar 

  66. Kumar SK, Mikhael JR, Buadi FK, et al. Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines. Mayo Clin Proc. 2009;84(12):1095–110.

    Article  PubMed  CAS  Google Scholar 

  67. Witzig TE, Laumann KM, Lacy MQ, et al. A phase III randomized trial of thalidomide plus zoledronic acid versus zoledronic acid alone in patients with asymptomatic multiple myeloma. Leukemia. 2012;27(1):220–5.

    PubMed  Google Scholar 

  68. Anderson KC, Alsina M, Bensinger W, et al. Multiple myeloma. J Natl Compr Canc Netw. 2011;9(10): 1146–83.

    PubMed  Google Scholar 

  69. Dimopoulos MA, Papadimitriou C, Anagnostopoulos A, Mitsibounas D, Fermand JP. High dose therapy with autologous stem cell transplantation for solitary bone plasmacytoma complicated by local relapse or isolated distant recurrence. Leuk Lymphoma. 2003;44(1):153–5.

    Article  PubMed  CAS  Google Scholar 

  70. Jantunen E, Koivunen E, Putkonen M, Siitonen T, Juvonen E, Nousiainen T. Autologous stem cell transplantation in patients with high-risk plasmacytoma. Eur J Haematol. 2005;74(5):402–6.

    Article  PubMed  CAS  Google Scholar 

  71. Alexanian R. Localized and indolent myeloma. Blood. 1980;56(3):521–5.

    PubMed  CAS  Google Scholar 

  72. Dimopoulos MA, Kiamouris C, Moulopoulos LA. Solitary plasmacytoma of bone and extramedullary plasmacytoma. Hematol Oncol Clin North Am. 1999;13(6):1249–57.

    Article  PubMed  CAS  Google Scholar 

  73. Mill WB, Griffith R. The role of radiation therapy in the management of plasma cell tumors. Cancer. 1980;45(4):647–52.

    Article  PubMed  CAS  Google Scholar 

  74. Hu K, Yahalom J. Radiotherapy in the management of plasma cell tumors. Oncology (Williston Park). 2000;14(1):101–8; 11; discussion 11–2; 15.

    Google Scholar 

  75. Susnerwala SS, Shanks JH, Banerjee SS, Scarffe JH, Farrington WT, Slevin NJ. Extramedullary plasmacytoma of the head and neck region: clinicopathological correlation in 25 cases. Br J Cancer. 1997;75(6): 921–7.

    Article  PubMed  CAS  Google Scholar 

  76. Dagan R, Morris CG, Kirwan J, Mendenhall WM. Solitary plasmacytoma. Am J Clin Oncol. 2009;32(6): 612–7.

    Article  PubMed  Google Scholar 

  77. Jyothirmayi R, Gangadharan VP, Nair MK, Rajan B. Radiotherapy in the treatment of solitary plasmacytoma. Br J Radiol. 1997;70(833):511–6.

    PubMed  CAS  Google Scholar 

  78. Strojan P, Soba E, Lamovec J, Munda A. Extramedullary plasmacytoma: clinical and histopathologic study. Int J Radiat Oncol Biol Phys. 2002;53(3):692–701.

    Article  PubMed  Google Scholar 

  79. Chao MW, Gibbs P, Wirth A, Quong G, Guiney MJ, Liew KH. Radiotherapy in the management of solitary extramedullary plasmacytoma. Intern Med J. 2005;35(4):211–5.

    Article  PubMed  CAS  Google Scholar 

  80. Galieni P, Cavo M, Pulsoni A, et al. Clinical outcome of extramedullary plasmacytoma. Haematologica. 2000;85(1):47–51.

    PubMed  CAS  Google Scholar 

  81. Shih LY, Dunn P, Leung WM, Chen WJ, Wang PN. Localised plasmacytomas in Taiwan: comparison between extramedullary plasmacytoma and solitary plasmacytoma of bone. Br J Cancer. 1995;71(1): 128–33.

    Article  PubMed  CAS  Google Scholar 

  82. Arbetter KR, Prakash UB, Tazelaar HD, Douglas WW. Radiation-induced pneumonitis in the “nonirradiated” lung. Mayo Clin Proc. 1999;74(1):27–36.

    Article  PubMed  CAS  Google Scholar 

  83. Anderson KC, Alsina M, Bensinger W, et al. NCCN clinical practice guidelines in oncology: multiple myeloma. J Natl Compr Canc Netw. 2009;7(9):908–42.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hematology, Department of Internal Medicine, Mayo Clinic, 200 First St SW, Rochester, MN, 55905, USA

    David Dingli M.D., Ph.D. & Prashant Kapoor M.D.

Authors
  1. David Dingli M.D., Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Prashant Kapoor M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to David Dingli M.D., Ph.D. .

Editor information

Editors and Affiliations

  1. Mayo Clinic, Department of Internal Medicine Division of Hematology, Rochester, Minnesota, USA

    Morie A. Gertz

  2. Mayo Clinic, Myeloma Amyloidosis Dysproteinemia Group Division of Hematology, Rochester, Minnesota, USA

    S. Vincent Rajkumar

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Mayo Foundation for Medical Education and Research

About this chapter

Cite this chapter

Dingli, D., Kapoor, P. (2014). Solitary Plasmacytoma. In: Gertz, M., Rajkumar, S. (eds) Multiple Myeloma. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-8520-9_16

Download citation

  • DOI: https://doi.org/10.1007/978-1-4614-8520-9_16

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4614-8519-3

  • Online ISBN: 978-1-4614-8520-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation